Illumine Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Illumine Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,782	Closed	-$2.56M	–	15
2026 Q1	$2.58M	Sell	5,782 -38	-0.7%	-$17.7K	1.98%	13
2025 Q4	$2.64M	Sell	5,820 -6	-0.1%	-$2.59K	1.92%	18
2025 Q3	$2.28M	Sell	5,826 -49	-0.8%	-$20.5K	1.63%	20
2025 Q2	$2.62M	Buy	5,875 +21	+0.4%	+$9.68K	2.08%	16
2025 Q1	$2.84M	Buy	5,854 +78	+1%	+$36.3K	2.32%	14
2024 Q4	$2.33M	Buy	+5,776	New	+$2.68M	1.91%	17

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Illumine Investment Management's VRTX Position: Q2 2026 in Review

Illumine Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 5,782 shares — an estimated $2.56M sold.

Illumine Investment Management first reported a position in VRTX in Q4 2024 and held it in 6 quarters. The position peaked at $2.84M in Q1 2025. 670 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Illumine Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Illumine Investment Management sold 5,782 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.56M.
Illumine Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Illumine Investment Management's Vertex Pharmaceuticals position peaked at $2.84M in Q1 2025.
670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Illumine Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.